Alkermes | Investor Day Presentation Deck | 144 slides · page 80 of 132
The slide outlines the transition from dose escalation cohorts (q7d and q21d) to a specific Phase 2 expansion cohort at 3.0 mg q7d.
Conference presentation · roadmap · plan_implementation · dense density
Slide locked Sign in to view
Slide schematic 5/5
callout 1/1 diagram 2/2 disclaimer 1/1 title 1/1
Components 5
primary process process disclaimer headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.